Inventor · disambiguated record
Christopher Ryan Morgan
Also filed as: MORGAN CHRISTOPHER RYAN
3 granted patents·11 pending applications·7 citations·filing 2014–2023
60Inventor score
Top patents by PatentIndex Score
14 records- 0185US12157771B2Proteins binding NKG2D, CD16 and CLEC12ADRAGONFLY THERAPEUTICS INC·Filed 2021·Granted Dec 3, 2024·1 cites·21 claims
- 0281US12377144B2Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2022·Granted Aug 5, 2025·1 cites·20 claims
- 0377US9845363B2Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereofSANOFI SA·Filed 2014·Granted Dec 19, 2017·5 cites·10 claims
- 0470US2023015181A1Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and Uses ThereofSANOFI SA·Filed 2022·Application pending·0 cites
- 0560US2023250176A1Ppharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0658US2023220106A1Antibodies targeting 5t4 and uses thereofDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0756US2019359729A1Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and Uses ThereofSANOFI SA·Filed 2019·Application pending·0 cites
- 0856US2023416402A1Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0956US2022195065A1Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatmentDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1055US2023203202A1Proteins binding nkg2d, cd16 and 5t4DRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1155US2023257467A1Proteins binding nkg2d, cd16 and egfrDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1254US2023279121A1Antibodies targeting egfr and use thereofDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1351US2018155444A1Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and Uses ThereofSANOFI SA·Filed 2017·Application pending·0 cites
- 1449US2023272041A1Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused ProteinsDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christopher Ryan Morgan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →